Growth hormone (GH) is secreted in a pulsatile pattern to promote body growth and metabolism. GH exerts its function by activating several signaling pathways, including JAK2/STAT and MEK/ERK. ERK1/2 activation by GH plays important roles in gene expression, cell proliferation and growth. We previously reported that in rat H4IIE hepatoma cells following an initial GH exposure, a second GH exposure induces STAT5 phosphorylation, but not ERK1/2 phosphorylation (Ji S., J Biol Chem 277:28384-28393 2002). In the present study, the mechanisms underlying GH-induced homologous desensitization were investigated. A second GH exposure activated the signaling intermediates upstream of MEK/ERK, including JAK2, Ras, and Raf-1. This correlated with recovery of GHR levels, but was insufficient for GH-induced phosphorylation of MEK1/2 and ERK1/2. Insulin restored the ability of a second GH exposure to induce phosphorylation of MEK1/2 and ERK1/2, without altering GHR levels or GHinduced phosphorylation/activation of JAK2 and Raf-1. GH and insulin synergized in promoting cell proliferation.
levels, respectively (25). Recovery of GHR, however, was insufficient for recovery of GH signaling via ERK1/2, suggesting that post-receptor mechanisms are involved. In the present study, the post-GHR mechanisms by which GH induced desensitization of ERK1/2 phosphorylation were investigated. Following an initial GH treatment, activation of JAK2, Ras, and Raf-1 was induced by a second GH treatment and correlated with recovery of GHR levels. However, this was insufficient to activate MEK1/2 and ERK1/2. Since insulin plays an important role in regulating GH signaling and action, the effects of insulin on a second GHinduced signaling pathways were also investigated. Prior exposure to insulin restored the ability of a second GH treatment to induce MEK/ERK phosphorylation, without changing GHR levels or GH-induced activation of JAK2 and Raf-1. GH and insulin synergized in promoting cell proliferation. Further investigation suggested that insulin increased the amount of MEK bound to KSR and restored the second GH-induced tyrosine phosphorylation of KSR. A previous GH exposure also resulted in desensitized phosphorylation of STAT1 and STAT3. However, insulin did not restore a second GH-induced phosphorylation of STAT1 and STAT3. Our study suggests that, in the liver, signaling via the MEK/ERK pathway may become resensitized to repeated GH pulses in the presence of insulin.
EXPERIMENTAL PROCEDURES
Materials -Bovine GH (bGH) was purchased from the National Institutes of Health NIDDK National Hormone & Pituitary Program. Fetal bovine serum, calf serum, and horse serum were purchased from Invitrogen (Carlsbad, CA). Rat leukemia inhibitory factor (LIF) was purchased from Chemicon (Temecula, CA). Other materials were purchased from Sigma (St. Louis, MO) and Fisher Scientific (Pittsburgh, PA), unless otherwise noted. Antibodies -Antibodies for Ras, Raf-1, MEK1/2, KSR, and STAT5B were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies for phospho-threonine (PT) 202 and phospho-tyrosine (PY) 204-ERK1/2, phospho-serine (PS) 218/222 MEK1/2, PS473-Akt, and PY694-STAT5B were purchased from Cell Signaling Technology (Beverly, MA). Antibodies for PY1007/1008-JAK2 and PS338-Raf-1, and anti-phospho-tyrosine antibody 4G10 were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Mouse Ras antibody was purchased from Oncogene Research Product (Cambridge, MA). Anti-GHR (AL47) and anti-JAK2 AL33 polyclonal serum were kindly provided by Dr. Stuart J. Frank (University of Alabama at Birmingham). Secondary antibodies, including HRP-linked anti-mouse antibody and antirabbit antibody, were purchased from Cell Signaling Technology (Beverly, MA). Cell Culture and Treatments -Rat H4IIE hepatoma cells (from ATCC) were cultured in Swim's medium supplemented with 10% serum (5% horse serum, 3% newborn calf serum, and 2% fetal calf serum) and 100 units/ml penicillin and 100 :g/ml streptomycin. At ~50% confluence, cells were removed from serum and maintained in serum-free (and bovine serum albumin-free) medium for 48 h prior to the start of experimental treatments. For the washing experiments, medium was removed by aspiration following the first exposure to GH, and the cells were gently rinsed twice with phosphate-buffered saline (PBS), followed by addition of GH-free, serum-free medium. Protein Extraction -Cells were collected in 0.5 ml lysis buffer containing20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 20 mM KCl, 20% glycerol, 0.2 mM EDTA, 2 mM Na 3 VO 4 , 10 mM NaF, 1% Triton X-100, 0.2 mM PMSF, 10 :g/ml aprotinin, and 10 :g/ml leupeptin. Cell lysates were gently rocked at 4°C for 1 h and then centrifuged at 10,000 x g for 10 min, and the supernatants were stored at -80°C until use. Cell lysate protein concentrations were measured by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA). Immunoprecipitation and Immunoblotting -For immunoprecipitation, 1 mg protein in lysis buffer was incubated with primary antibody overnight at 4°C. Protein G-agarose (Fast flow, Pharmacia Biotech, Providence, RI) was then added, and incubations continued for 4 h at 4°C. Both immunoprecipitated proteins and whole cell lysate protein (50 :g) were resolved by SDS-PAGE (BioRad MiniProtean II system, Hercules, CA) and transferred to S&S Protran BA85 membranes (Keene, NH). The Western blots were blocked in Tris Buffered Saline containing 0.05% Tween (TBST) and 5% milk, rinsed in TBST, incubated with the primary antibody for 2 h at room temperature or overnight at 4°C, washed in TBST, and then incubated with HRP-labeled conventional secondary antibody for 1 h at room temperature. Proteins were visualized by ECL Plus (Amersham Biosciences, Piscataway, NJ) or Supersignal West Femto Maximum Sensitivity Substrate reagents (Pierce, Rockford, IL) and autoradiography. Determination of GTP-bound Ras -According to the manufacturer's instructions, cells were lysed with Mg-containing Lysis Buffer (MLB) containing 25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 10% glycerol, and 25 mM NaF. 10 :g of Raf-1 Ras-binding domain (RBD) agarose (Upstate Biotechnology, Inc.) was added to 1 mg of cell lysate and gently rocked at 4°C for 30 minutes. The agarose beads were washed three times with MLB and boiled in Laemmli sample buffer for 5 min, and the supernatant was then resolved by SDS-PAGE and transferred to Protran BA85 membrane. GTPbound Ras was determined by immunoblotting with total Ras antibody. BrdU Incorporation Assay -H4IIE cells (8x10 4 ) were seeded and cultured in 6-well plates. Cells were then treated as described in Cell Culture and Treatment, followed by the addition of BrdU (1 :M) to the medium. After 12 h, cells were stained using a BrdU assay kit (BD Pharmingen) according to the manufacturer's instructions. Samples were analyzed by flow cytometry for fluorescence on a FACScan. Densitometric and Statistical AnalysisChemiluminescent images of immunoblots were analyzed by scanning densitometry. Multiple exposures of each blot were used to obtain grayscale images of each chemiluminescent band and were quantified with the Fluorchem FC imager system (Alpha Innotech, San Leandro, CA). All data were analyzed by analysis of variance using the InStat statistical program (version 3) by GraphPad Software, Inc. (San Diego, CA), with * or # = p < 0.05, ** or ## = p < 0.01, *** or ### = p < 0.001, NS = no significant difference, upon comparison to the corresponding control group.
RESULTS

GH induced tyrosine phosphorylation of JAK2 following 1 h GH pretreatment plus a washout period.
In young adult male rats, GH is secreted in ~1 h pulses with ~ 3 h inter-pulse intervals of non-detectable GH (16) . We previously reported that: 1) a short exposure to GH rapidly reduced GHR levels which resulted in desensitization of STAT5 and ERK1/2 phosphorylation; 2) in the absence of GH for 3-6 h, GHR levels and GHinduced tyrosine phosphorylation of STAT5 (PY-STAT5) recovered to 65-75% of that in cells not pretreated with GH; and 3) unlike STAT5 phosphorylation, the ability of GH to activate the MEK/ERK pathway did not recover even following prolonged (16 h) incubation in the absence of GH (25). In order to allow the cells to maximally recover GHR levels and GH sensitivity, and to mimic a minimum of 3-4 h interpulse interval in vivo, we chose 5 h as the GH-free, serum-free incubation time. Therefore, to investigate the mechanisms by which GH induced desensitization of the ERK1/2 phosphorylation, H4IIE cells were pretreated with GH for 1 h, then incubated in GHfree, serum-free medium for 5 h, followed by a second GH treatment.
Following GH binding to GHR, JAK2 is phosphorylated and transphosphorylates GHR. We first characterized the effects of GH pretreatment on GH-induced tyrosine phosphorylation of JAK2 (PY-JAK2). GH significantly induced PY-JAK2 by 5 min, reaching a peak by 7.5 min, and decreasing after 10 min (Fig. 1A and 1B) . When H4IIE cells were pretreated with GH for 1 h followed by 5 h in GH-free, serum-free medium, the second GHinduced PY-JAK2 was maximally 70-75% of that induced by GH prior to any pretreatment ( Fig. 1A and 1B), correlating well with the recovery of GHR levels that we previously reported (25). This suggests that, after the initial exposure to GH, the second GH exposure was able to induce PY-JAK2. Total JAK2 protein levels were not altered, following any of the GH exposures or the washing regimens (Fig. 1A) .
GH induced GTP-bound Ras following GH pretreatment and GH-free incubation. Activation of theGHR/JAK2 complex activates Shc, which by guest on October 30, 2017 http://www.jbc.org/ Downloaded from recruits Grb2/SOS to the cell membrane, where SOS can convert Ras from the GDP-bound (inactive) to the GTP-bound (active) form. Whether a second GH exposure induced Ras activation was next examined. GTP-bound Ras was induced by GH at 5 min, with a maximal increase by 7.5 min and decreased significantly by 30 min ( Fig. 2A and 2B) . Following GH pretreatment and GH-free incubation for 5 h, GH-induced GTP-bound Ras was 70-75% of that induced by the initial GH treatment ( Fig. 2A  and 2B ), suggesting that the ability of the second GH treatment to activate Ras was not altered by previous GH treatment and correlated with the recovery of GHR levels and GH-induced PY-JAK2.
To control for equal loading and to determine whether the effects on GTP-bound Ras was dependent on changes in the total amounts of Ras protein, whole cell lysates were directly subjected to Western blot analysis by total Ras antibody. The total cellular amount of Ras protein was not significantly affected by GH pretreatment ( Fig. 2A) .
A second GH treatment induced serine 338 phosphorylation of Raf-1. We next examined the ability of a second GH treatment to activate Raf-1, immediately downstream of Ras. Phosphorylation of serine 338 on Raf-1 (PS338-Raf-1) is required for Raf-1 activation (26). In H4IIE cells, the first GH treatment induced PS338-Raf-1 maximally by 10 min, and decreased thereafter ( Fig. 3A and 3B ). The peak of PS338-Raf-1 induced by the second GH exposure at 10 min was about 55% of that induced by the first GH (Fig. 3B) . However, prior to the second GH treatment, the basal levels of PS338-Raf-1 were significantly reduced, and were only about 70% of the basal values prior to the first GH application (Fig. 3B , 0 time point, dashed line vs. solid line). Thus, when expressing the induction of PS338-Raf-1 compared to the reduced basal value, there was approximately a 1.6-fold induction by the second GH treatment. This 1.6-fold induction of PS338-Raf-1 is less than the approximately 2.1-fold induction by the first GH treatment. Therefore, the fold induction of PS338-Raf-1 by the second GH treatment was only 76% of that of the first GH treatment. Total Raf-1 protein abundance was not changed, following the second versus the first GH exposure (Fig. 3A) . Collectively, the data from Figs. 1-3 suggest that, after the previous GH treatment, the second GH treatment was able to activate JAK2, Ras, and Raf-1, and their activation was correlated well with the recovery of GHR levels (25).
Phosphorylation of MEK1/2 and ERK1/2 induced by a second GH treatment was not correlated with activation of the JAK2/Ras/Raf-1 pathway. When H4IIE cells were pretreated with GH for 1 h followed by 5 h in GH-free, serum-free media, the GH-induced phosphorylation of MEK1/2 ( Fig. 4A and 4B ) and ERK1/2 ( Fig. 4C and 4D) were greatly diminished compared with that induced by GH prior to any pretreatment. The first GH treatment induced serine phosphorylation of MEK1/2 (PS-MEK1/2) maximally by 10 min, and decreased thereafter ( Fig. 4A and 4B ). The PS-MEK1/2 induced by the second GH treatment was 27% or less than that induced by the first exposure ( Fig. 4A and 4B ). The second GH treatment did not achieve greater than 10-15% of the P-ERK1/2 induced by the first GH treatment ( Fig. 4C and 4D) , consistent with our previous findings (25).
Consistent with our previous study, GHR levels and GH-induced PY-STAT5 recovered by 65-70% [ Fig. 4E ; (25)]. In the present study, the maximal activation of signaling intermediates upstream of MEK/ERK, including JAK2, Ras, and Raf-1, induced by the second GH treatment was about 70-75% of that induced by the first GH treatment (Fig. 4E) , possibly resulting from the recovered GHR levels, and similar to GH-induced PY-STAT5. However, the ability of the second GH treatment to activate MEK/ERK was only 15-25% of that induced by the first GH treatment, suggesting a disconnect of signal transduction from Raf-1 to MEK1/2 (Fig. 4E) .
GH induced desensitization of STAT1 and STAT3 phosphorylation. GH can activate two other STATs, STAT1 and STAT3, in addition to STAT5 in H4IIE cells (27) . A second GH treatment can induce PY-STAT5 in H4IIE cells (25), but it was not known whether STAT1 and STAT3 can be activated by a second GH treatment. Therefore, the ability of a second GH treatment to activate/phosphorylate these two STATs was also examined. The first GH treatment induced a maximal 15-fold tyrosine phosphorylation of STAT1 (PY-STAT1) ( and 5B) and 6-fold of PY-STAT3 ( Fig. 5C and 5D ). Consistent with our previous report (25), PY-STAT5 was induced by the second GH treatment (Fig. 5A,  row 2 ), but to a lesser degree due to GHR being only recovered by ~65-75% at this time point. Unlike PY-STAT5, little PY-STAT1 was induced by the second GH treatment (Fig. 5A, row 1; Fig. 5B ). Basal PY-STAT3 levels were elevated after 5 h incubation in the absence of GH following the initial GH treatment ( Fig. 5C; Fig. 5D , dashed line, 0 time point). On the top of this elevated basal PY-STAT3 levels, there was no significant induction of PY-STAT3 observed in cells exposed to the second GH treatment ( Fig. 5C and 5D ). However, leukemia inhibitory factor (LIF), another JAK activator, was still able to fully stimulate phosphorylation of STAT1 and STAT3 following removal of GH and incubation in GH-free, serum-free medium ( Fig. 5A and 5C, rows 1). Therefore, similar to the MEK/ERK pathway, but unlike STAT5, the first GH treatment led to desensitization of the ability of a second GH treatment to induce PY-STAT1 and PY-STAT3.
Insulin restored a second GH-induced ERK1/2 phosphorylation. In adult male rats, insulin normally peaks in the middle of GH interpulse interval (28). Insulin is known to maintain GHR levels in vivo, which may be related to the growthpromoting effects of insulin (29-33). But the possible effects of insulin on repeated GH-induced signaling have yet to be studied. Therefore, we examined whether insulin affected GH-induced signaling pathways following a second exposure to GH. To mimic the in vivo GH and insulin secretory pattern, H4IIE cells were exposed to GH for 1 h, incubated in the absence of GH for 3 h, and then treated with insulin for 2 h, followed by a second GH treatment (the time between two GH treatments was held at 5 h).
As shown in Fig. 4 , in the absence of GH for 5 h following the first GH treatment, a second GHinduced P-ERK1/2 was barely observed, compared to the first GH treatment (Fig. 6A , row 1, lanes 2 vs. 4; Fig. 6B ). However, with insulin pretreatment for 2 h, the second GH treatment significantly induced P-ERK1/2, reaching approximately 70% of that induced by the first GH treatment (Fig. 6A , row 1, compare lanes 2 and 4 to lane 7; Fig. 6B ). This induction was much greater than the sum of P-ERK1/2 induced by the second GH for 10 min without insulin treatment (Fig. 6A , row 1, lane 4) plus the P-ERK1/2 induced by insulin treatment for 2 h (Fig. 6A , row 1, lane 6).
Since the GH interpulse interval in male rats is about 3 h, we then asked whether insulin had similar effects when given in the middle of a 3 h GH interpulse interval. Similarly, insulin pretreatment for 1 h also significantly restored the ability of a second GH treatment to induce P-ERK1/2 ( Fig. 6C  and 6D ). Therefore, we chose 3 h GH interpulse interval and 1 h insulin treatment in the following investigation of the mechanisms by which insulin restored GH-induced P-ERK1/2.
Since insulin also activates ERK1/2, it could not be excluded that the second GH exposure potentiates insulin activation via ERK1/2. The other major signaling pathway activated by insulin is the PI3K/Akt pathway, therefore the effects of the second GH treatment on insulin-induced phosphorylation of Akt was also investigated. GHinduced P-Akt in H4IIE cells was weak (Figs. 6A and 6C, rows 3, lanes 2). Insulin-induced P-Akt remained highly elevated following insulin treatment for 2h or 1h (Figs. 6A and 6C, rows 3, lanes 6) and the second addition of GH did not affect insulininduced P-Akt levels (Figs. 6A and 6C, rows 3, lanes 7). Our previous work (34) also suggests that the time-course of ERK1/2 activation by insulin and by GH in H4IIE cells are different. GH induced P-ERK1/2 with a maximal induction by 10 min, and returned towards basal levels after 20 min. In contrast, insulin-induced P-ERK1/2 peaks by 5 min, which quickly decreases after 5 min reaching a secondary plateau level and returning towards basal levels between 60 and 120 min. In the present study, following the first GH exposure, incubation in serum-free medium plus insulin treatment, and then a second exposure to GH, P-ERK1/2 peaked at 10 min, and then returned towards basal levels after 20 min (data not shown). Therefore, the resensitization of P-ERK1/2 following the second GH addition occurred over the normal GH time course, not the insulin time course (quicker and more prolonged). Our data strongly suggests that insulin re-sensitizes GH-induced ERK1/2 signaling. 7) . Therefore, the effects of insulin on a second GH-induced signaling were selective to the ERK1/2 pathway, but not to STATs including STAT5, STAT1, or STAT3.
Insulin did not affect a second GH-induced
Insulin did not alter GHR levels or a second GH-induced activation of JAK2 and Raf-1. As previously reported (25), GH treatment for 10 min resulted in a reduction of GHR levels by ~50% (Fig.  8A, lanes 1 vs. 2; Fig. 8B ). Following 3 h in GHfree, serum-free medium, the GHR levels recovered to 60 (Fig. 8A, lanes 3 and 5 vs. 6; Fig. 8B ), nor alter the further reduction of GHR by the second GH exposure (Fig. 8A, lanes 4 vs. 7; Fig. 8B ).
As described in Fig. 1 , PY-JAK2 induced by a second GH treatment peaked at 5 min (Fig. 8C,  row 1, lanes 1-3; Fig. 8D ). Following 3 h in GHfree, serum-free medium, PY-JAK2 induced by the second GH treatment at 5 and 10 min was between 60-75% of that induced by the first GH (Fig. 8C , row 1, lanes 2 vs. 5, lanes 3 vs. 6; Fig. 8D ), correlating with the recovery of GHR levels. There was no significant effects of insulin on a second GHinduced PY-JAK2 (Fig. 8C, row 1, lanes 7-9; Fig.  8D ). It was also found that insulin pretreatment did not affect the second GH-induced Raf-1 kinase activity (data not shown), determined by an in vitro kinase assay. Therefore, the resensitization of GHinduced ERK1/2 phosphorylation by insulin was not due to a change of GHR levels or activation of JAK2 and Raf-1.
Insulin restored the ability of a second GH treatment to induce MEK1/2 phosphorylation. We next examined whether a second GH following insulin treatment was able to induce PS-MEK1/2. When H4IIE cells were treated with GH for 1 h followed by 3 h GH-free incubation, the second GHinduced PS-MEK1/2 was greatly diminished compared with the first GH [ GH and insulin synergized in promoting cell proliferation. It was then examined whether the combined action of insulin and a second GH exposure on the ERK1/2 pathway led to any effects in a biological response to GH. GH is a known hepatic mitogen and liver size is increased compared to other organs and body size in response to GH (35-37). When cells were treated with one GH treatment (G1), two repeated GH treatments (G1/G2), or one GH treatment followed by insulin (G1/I), the cell proliferation rate was similar to control cells (30% of the cells were BrdU-positive), suggesting a lack of effects of these treatments on cell proliferation (Fig. 10) . However, two GH treatments in the presence of insulin (G1/I/G2) significantly increased cell proliferation (40% of the cells were BrdUpositive) compared to control cells. As a positive control, 70% of the cells were BrdU-positive when grown in complete medium. Therefore, a GH treatment was capable of increasing liver cell proliferation when, and only when, cells had been pretreated with insulin.
Insulin increased the amount of MEK bound to KSR and restored a second GH-induced tyrosine phosphorylation of KSR.
Since insulin restored the ability of a second GH treatment to activate MEK/ERK without affecting GHR levels and activation of JAK2 and Raf-1, we next investigated the underlying mechanisms. Kinase suppressor of Ras (KSR), a scaffolding protein for the Ras/Raf-1/MEK/ERK pathway, brings Raf-1 and MEK closer to each other and facilitates the activation of MEK by Raf-1 (38-41). The interaction between Raf-1 or MEK and KSR was examined by coimmunoprecipitation assay. Compared with cells untreated with insulin, the amount of KSR immunoprecipitated with KSR antibody consistently decreased following 1 h of insulin treatment in the absence or presence of a second GH (Fig. 11A , row 1, lanes 1-5 vs. lanes 6 and 7). However, when whole cell lysates were directly subjected to Western blot analysis, the total cellular KSR abundance was not changed (Fig. 11A , row 5), and there was also no change in total STAT1 protein which was used as a loading control (Fig. 11A, row 6 ). This suggests that pretreatment with insulin, possibly by inducing a conformational change or by some other mechanism, modestly decreases the ability of KSR to be immunoprecipitated.
The amount of Raf-1 or MEK bound to KSR was not significantly affected by the first GH treatment (Fig. 11A, rows 2 and 3, lanes 2 vs. 1) , whereas the amount of Raf-1 bound to KSR significantly increased following the first GH treatment and incubation in serum-free, GH-free medium for 3 h or 2 h (Fig. 11A, row 2, lanes 3 and  5) . Following insulin pretreatment for 1 h without or with the second GH treatment, the amount of MEK co-immunprecipitated with KSR actually increased when normalized to the reduced amount of immunoprecipitated KSR (Fig. 11A, row 3, lanes 6  and 7; Fig. 11C ). For this normalization, the amount of Raf-1 or MEK bound to KSR was divided by the levels of KSR immunoprecipitated on the same blot. Although insulin significantly increased KSR-bound MEK, but it did not affect the ratio of KSR-bound Raf-1 vs. KSR (Fig. 11B) . The second GH treatment did not alter the amount of Raf-1 bound to KSR and this was true when the cells were pretreated with insulin or not (Fig. 11B) . The second GH following insulin pretreatment did not alter the KSR-bound MEK that was increased by insulin pretreatment (Fig. 11C) . Taken together, this suggests that, following insulin pretreatment, the second GH treatment induced activation of MEK and ERK without further increasing the ability of Raf-1 or MEK to associate with KSR.
Studies suggest a potential role of KSR phosphorylation in its function (42;43). To ask whether GH or insulin treatment could regulate KSR function, the effects of GH or insulin on the phosphorylation status of KSR was examined. The levels of PY-KSR were also normalized to the levels of immunoprecipitated KSR. The first GH treatment induced tyrosine phosphorylation (PY) of KSR by 8-fold, whereas a second GH treatment induced only a 4-fold increase of PY-KSR (Fig. 11A, row 4 , lanes 2 and 4, respectively, and Fig. 11D ). After incubation in GH-free, serum-free medium for 2 h or 3 h, PY-KSR levels returned to basal values. Following insulin treatment for 1 h, PY-KSR levels were elevated approximately 4-fold, an effect of insulin. However, a second exposure to GH following insulin treatment induced a large, 14-fold increase of PY-KSR (Fig. 11D) . This large induction of PY-KSR, above the induction by insulin, suggests that the insulin pretreatment restored the ability of a second GH to robustly induce PY-KSR.
DISCUSSION
We previously reported that, after an initial GH treatment, ERK1/2 phosphorylation becomes desensitized to a second GH treatment, possibly due to post-receptor mechanisms (25). In human IM-9 lymphocytes, two continuous GH pulses without an interpulse interval resulted in a desensitized tyrosine phosphorylation of JAK2 (44). However, in the present study of rat H4IIE hepatoma cells where there was a GH-free interval between GH treatments, a second GH was able to activate JAK2. The extent of JAK2 phosphorylation correlated well with the recovery of GHR levels and GH-induced STAT5 phosphorylation. This indicates that the absence of GH between two GH applications is required for the recovery of JAK2/STAT5 phosphorylation. In agreement with this, in male by guest on October 30, 2017 http://www.jbc.org/ Downloaded from rats, even a nominal GH pulse during the usual GHdevoid interpulse interval of the masculine GH secretory profile results in a complete repression of STAT5-dependent male-specific expression of CYP2C11, CYP3A2, and CYP2A2 (45).
The recovery of JAK2 activation following the GH-free period led to a similar recovery of activation of STAT5, Ras, and Raf-1, but not MEK/ERK.
This suggests that GH-induced homologous desensitization of the MEK/ERK pathway is due to a defect in signal transduction from Raf-1 to MEK1/2. Several recent studies have focused on the mechanisms underlying homologous desensitization of intracellular signaling. Treatment with insulin or growth factors results in homologous desensitization of the Ras/Raf-1/MEK/ERK pathway, and this desensitization can occur at receptor or post-receptor levels. Ras desensitization induced by epidermal growth factor or plateletderived growth factor is due to the loss of their functional cell surface receptors, whereas insulininduced desensitization of Ras results from the dissociation of SOS from Grb2 (46). Our data indicates that GH-induced desensitization of ERK1/2 signaling pathway is not caused by the change of GH receptor levels or Ras desensitization, but by a defective signal transduction from Raf-1 to MEK1/2, thus suggesting a novel post-receptor mechanism of homologous desensitization.
Although STAT5 is the predominant STAT utilized by GH to regulate gene transcription, STAT1 and STAT3 are also involved in GHinduced gene expression (19;47-50) . We previously reported that GH activates all three STATs in H4IIE cells, STAT1, STAT3, and STAT5 (27). In the present study, previous GH treatment desensitized the ability of a second GH to induce phosphorylation of STAT1 and STAT3 but not STAT5, which is consistent with in vivo findings (19) . Following a GH pulse, activation of STAT5 in rat liver is fully restored when a second GH pulse is given 4 h later. The low steady-state level of tyrosinephosphorylated STAT1 and STAT3 in male rat liver may be due to the desensitized STAT1 and STAT3 (19) .
The mechanisms underlying the differential desensitization of STAT1, STAT3, and STAT5 are unknown, but may involve an activation of negative regulators specific for STAT1 and STAT3 proteins or their phosphotyrosine-binding sites on the GHR/JAK2 complex. The phosphotyrosine-binding sites on GHR/JAK2 complex used by STAT5 are different from those of STAT1 and STAT3. Binding to phosphorylated tyrosines in the cytoplasmic domain of GHR is required for GHinduced STAT5 activation (51;52), but not for GH to activate STAT1 and STAT3 (53) (54) (55) (56) (57) . This is further supported by a C-terminal GHR mutation recently identified in a patient with severe short stature and biochemical features of GH insensitivity. This GHR mutant results in impaired STAT5 but normal STAT3 signaling (58) . Furthermore, JAK2 but not GHR, contains STAT3 association motifs and a STAT1-like association motif (59;60), suggesting that JAK2 not only phosphorylates STAT1 and STAT3 but also provides binding sites for their association with the GHR/JAK2 complex.
Growth hormone-activated STAT signaling is also negatively regulated by a number of proteins, including the suppressors of cytokines signaling (SOCS) (SOCS1-7 and CIS) and protein tyrosine phosphatases. Of the eight known members of the SOCS family, GH induces expression of SOCS-1, -2, -3, and CIS in rat liver (61) (62) (63) . SOCS/CIS proteins bind to GHR or JAK2 via their phosphotyrosine-binding SH2 domains and inhibit the kinase activity of JAK2 or compete with STAT5 for receptor docking sites (63;64) . In addition, the SH2 domain-containing phosphatase-1, and -2 have been implicated in dephosphorylation of tyrosines on GHR or JAK2 (65-69). However, negative regulators specific for STAT1 or STAT3, but not for STAT5, have not been reported. Therefore, the putative role of SOCS and phosphatases in STAT1/STAT3 desensitization, but not STAT5 desensitization can only be hypothesized.
Insulin plays an important role in regulating GH signaling and action, which may partially explain insulin's growth-promoting effect. In vivo, insulin appears to be necessary for normal liver GH responsiveness, in part by maintaining liver GHR levels (29-32). It was reported nearly 20 years ago that insulin peaks in the middle of a GH interpulse interval in male rats (28), but the possible effects of insulin on repeated GH pulse-induced signaling have not been studied. In the present study, we found that insulin selectively restored the ability of a second GH treatment to induce MEK/ERK phosphorylation. Liver ERK1/2 can be activated by a single GH injection (70), but it is not known whether it can be activated by multiple GH pulses or whether the steady-state levels of phosphorylated ERK1/2 is high in intact male rat liver. The current study suggests that multiple GH pulses may be able to reactivate ERK1/2 in vivo, following a peak of insulin secretion.
The synergistic effects of GH and insulin in promoting cell proliferation suggest that repeated GH pulse-induced ERK1/2 activation, in the presence of insulin, may be necessary for liver growth.
GH transgenic mice demonstrate significantly increased growth of internal organs, but the liver in particular is enlarged compared to other organs (35;37) and there is life-long high levels of hepatocellular replication in this model (36). GH also plays a critical role in liver regeneration after hepatectomy (71). It is not clear which pathway is responsible for the action of GH in hepatocyte proliferation, but the ERK1/2 pathway is a potential candidate in the growth response to many growth factors including GH, given that activation of ERK1/2 pathway is frequently associated with cell proliferation. Furthermore, the decreased growth in children with type 1 diabetes has been substantially improved by daily multiple-dose insulin treatment, compared to single-dose insulin treatment (72) (73) (74) . It is possible that improvements in growth are related to, in part, the effects of insulin on GHinduced ERK1/2 activation.
Although insulin restored a second GHinduced MEK/ERK phosphorylation, it did not affect GHR levels and GH-induced phosphorylation JAK2 and STAT5. Tyrosine phosphorylation of STAT1 and STAT3 remained insensitive to a second GH treatment in H4IIE cells no matter whether insulin was present or not. This is consistent with the in vivo findings that liver tyrosinephosphorylated STAT1 and STAT3 levels in intact male rats are as low as in female rats (19) . The low levels of tyrosine-phosphorylated STAT1 and STAT3 in male liver may be due to the desensitization of STAT1 and STAT3 following a previous exposure to GH and an inability to become resensitized during the low GH concentration interpeak interval. This suggests that STAT1 and STAT3 are not primary players in the sex-specific patterns of liver gene expression and body growth because these two STATs, unlike STAT5, may not be reactivatable by the masculine GH secretory pattern. In addition, STAT3 plays an important role in the acute phase response, and liver-specific STAT3 knockout mice exhibited an impaired acute phase response in liver (75) . GH can regulate the expression of acute phase proteins (76) (77) (78) , but the desensitization of STAT3 to repeated GH pulses suggests that STAT3 may not be the major pathway utilized by GH to regulate acute phase protein expression.
In H4IIE cells, following the initial GH treatment plus a GH-free incubation, a second GH treatment was able to activate JAK2, Ras, and Raf-1 but not MEK/ERK. Insulin restored the ability of a second GH treatment to activate MEK/ERK, but did not alter the activation of JAK2 and Raf-1, suggesting that insulin restores the disrupted signal transduction from Raf-1 to MEK1/2 caused by the previous GH treatment. KSR plays an integral role in scaffolding of Ras/Raf-1/MEK/ERK pathway proteins. After growth factor stimulation, KSR colocalizes MEK1/2 into close proximity with Raf-1 and allows Raf-1 to phosphorylate MEK1/2 (38-41). In the KSR knock-out mouse, Ras and Raf-1 activation is normal, but MEK1/2 and ERK1/2 activation is defective, indicating KSR is required for proper activation of MEK1/2 and ERK1/2 in the Ras/Raf/MEK/ERK pathway (79) .
Similar to the disruption of the MEK/ERK pathway in the KSR knock-out mouse, a second GH treatment in the present study normally activated Ras and Raf-1, but not MEK1/2 and ERK1/2. The desensitization of MEK1/2 in response to the second GH treatment was associated with increased Raf-1/KSR interaction but reduced tyrosine phosphorylation of KSR. Insulin pretreatment increased the amount of MEK bound to KSR. More importantly, insulin also restored the ability of a second GH treatment to activate MEK and this was correlated with a recovery of tyrosine phosphorylation of KSR. The function of tyrosine phosphorylation of KSR is unknown, however, the present findings lead us to hypothesize that it may cause a conformational change of KSR protein and by guest on October 30, 2017 http://www.jbc.org/ Downloaded from thereby position the activator Raf-1 in close proximity to its substrate MEK, so that activation of MEK by Raf-1 could proceed (Fig. 12) .
In summary, GH-induced desensitization of MEK/ERK phosphorylation was not due to a deficiency in activation of JAK2, Ras, or Raf-1, but resulted from a defective signal transduction from Raf-1 to MEK1/2, possibly due to the reduced tyrosine phosphorylation of KSR. Insulin restored the ability of a second GH treatment to induce MEK/ERK phosphorylation without affecting GHR levels and phosphorylation/activation of JAK2 and Raf-1, possibly by increasing the amount of MEK bound to KSR and also restoring GH-induced tyrosine phosphorylation of KSR. Previous GH treatment also induced a desensitization of STAT1 and STAT3 phosphorylation.
However, resensitization by insulin was selective for MEK/ERK pathway, since insulin failed to reverse the impaired phosphorylation of STAT1 and STAT3.
Therefore, adequate insulin secretion may be necessary for multiple GH pulses to reactivate the MEK/ERK pathway. Activation of ERK1/2 may mediate GH-induced cell proliferation, differentiation and gene expression (9;11;70;80;81). ERK1/2 may also play an important role in mediating the growth-promoting effects of GH (82) (83) (84) (85) . However, when insulin secretion is deficient, such as in type 1 diabetes or with malnutrition, all of these important GH actions, mediated by ERK1/2, may be lost due to the desensitization induced by prior GH exposure. Fig. 1 . GH-induced PY-JAK2 following 1 h GH pretreatment plus a wash-out period. H4IIE cells were treated with a first GH exposure (500 ng/ml; GH1; solid line) for 1 h, or a second GH exposure (500 ng/ml; GH2; dashed line) following the first exposure to GH and 5 h in GH-free, serum-free medium, or vehicle for the indicated times. Western blot analysis was performed with antibodies for phospho-tyrosine (PY)-JAK2. The blot was reprobed with total JAK2 antibody as a loading control. A) Representative Western blots. The PY-JAK2 band is indicated by the arrow. B) Densitometric analysis of autoradiographs from 3 separate experiments to quantify PY-JAK2 levels. The data are expressed as mean ± S.E. The PY-JAK2 levels following 7.5 min of 500 ng/ml GH1 were arbitrarily set to 100%. The PY-JAK2 band is indicated by the arrow. Fig. 2 . GH induced GTP-bound Ras following GH pretreatment and GH-free incubation. H4IIE cells were treated with GH1 or GH2 or vehicle for the indicated times as described in the legend for Fig.1 . Whole cell lysates were affinity-precipitated with Raf-1 RBD agarose and then subjected to Western blot analysis by total Ras antibody to detect the activated Ras (upper panel), or whole cell lysate was directly resolved to SDS-PAGE and transferred to the membrane, followed by probing with total Ras antibody as a loading control (lower panel). A) Representative Western blots. B) Densitometric analysis of autoradiographs from 3 separate experiments to quantify activated Ras (Ras-GTP) levels. The data are expressed as mean ± S.E. The Ras-GTP levels following 7.5 min of 500 ng/ml GH1 were arbitrarily set to 100%. Fig. 3 . A second GH treatment induced serine 338 phosphorylation of Raf-1. H4IIE cells were treated with GH1 or GH2 or vehicle for the indicated times as described in the legend for Fig.1 . Western blot analysis was performed with phospho-serine (PS)338-Raf-1 antibody, followed by stripping and reprobing with total Raf-1 antibody. A) Representative Western blots. B) Densitometric analysis of autoradiographs from 3 separate experiments to quantify PS338-Raf-1 levels. The data are expressed as mean ± S.E. The PS338 levels following 10 min of 500 ng/ml GH1 were arbitrarily set to 100%. Fig. 4 . Phosphorylation of MEK1/2 and ERK1/2 induced by a second GH treatment was not correlated with activation of the JAK2/Ras/Raf-1 pathway. H4IIE cells were treated with GH1 or GH2 or vehicle for the indicated times as described in the legend for Fig.1 . Western blot analysis was performed with antibodies for PS-MEK1/2 or P-ERK1/2, followed by stripping and reprobing with antibodies for total MEK1 or ERK1/2. A and C) Representative Western blots. The PS-MEK band is indicated by the arrow. B and D) Densitometric analysis of autoradiographs from 3 separate experiments to quantify PS-MEK1/2 and P-ERK1/2 levels. The data are expressed as mean ± S.E. The PS-MEK1/2 (C) or P-ERK1/2 (D) levels following 10 min of 500 ng/ml GH1 were arbitrarily set to 100%. (E) Maximal activation of signaling intermediates induced by GH2. The data are expressed as mean ± S.E. The PY-JAK2 or Ras-GTP levels following 7.5 min of 500 ng/ml GH1 were arbitrarily set to 100%. The PS-Raf-1, PS-MEK1/2, or P-ERK1/2 levels following 10 min of 500 ng/ml GH1 were arbitrarily set to 100%. The GHR levels and GH-induced PY-STAT5 were obtained from our previous report (25). Fig. 5 . GH induced desensitization of STAT1 and STAT3 phosphorylation. H4IIE cells were treated with GH1, GH2, LIF (leukemia inhibitory factor; 50 ng/ml), or vehicle for the indicated times as described in the legend for Fig.1 . Western blot analysis was performed with antibodies for PY-STAT1 or PY-STAT3, followed by stripping and reprobing with antibodies for total STAT1 or STAT3. A and C) Representative Western blots. B and D) Densitometric analysis of autoradiographs from 3 separate experiments to quantify PY-STAT1 and PY-STAT3 levels. The data are expressed as mean ± S.E. The PY-STAT1 (B) or P-STAT3 (D) levels were shown as a fold change compared to control (untreated) which were arbitrarily set to 1. Fig. 6 . Insulin restored a second GH-induced ERK1/2 phosphorylation. H4IIE cells were treated with GH1 or vehicle for the indicated times, washed, and incubated in GH-free, serum-free medium for 5 h or 3 h. They were then treated without or with 10 nM insulin for 2 h or 1 h, and followed by GH2. Western blot analysis was performed with antibody for P-ERK1/2 and P-Akt, followed by stripping and reprobing with antibody for total ERK1/2 and total Akt as loading controls. A and C) Representative Western blots. B and D) Densitometric analysis of autoradiographs from 3 or more separate experiments were performed to quantify P-ERK1/2 levels. The data are expressed as mean ± S.E. The P-ERK1/2 levels in untreated samples were arbitrarily set to 1. Western blot analysis was performed as described in the legend for Fig. 6 , except for the use of antibodies for PY-STAT1, PY-STAT3, PY-STAT5, total STAT1 and total STAT3. A) Representative Western blots of at least 3 separate experiments with insulin pretreatment for 60 min. B) Densitometric analysis of autoradiographs from at least 3 separate experiments were performed to quantify PY-STAT5 levels. The data are expressed as mean ± S.E. The PY-STAT5 levels in untreated samples were arbitrarily set to 1. Fig. 8 . Effects of insulin on GHR levels and a second GH-induced PY-JAK2. Western blot analysis was performed as described in the legend for Fig. 6 , except for the use of antibodies for GHR, PY-JAK2 and total JAK2. A and C) Representative Western blots. B and D) Densitometric analysis of autoradiographs from at least 3 separate experiments were performed to quantify GHR and PY-JAK2 levels. The data are expressed as mean ± S.E. The GHR and PY-JAK2 levels in untreated samples were arbitrarily set to 1. Fig. 9 . Insulin restored the ability of a second GH treatment to induce MEK1/2 phosphorylation. Western blot analysis was performed as described in the legend for Fig. 6 , except for the use of antibodies for PS-MEK1/2 and total MEK1/2. A) Representative Western blots. B) Densitometric analysis of autoradiographs from at least 3 separate experiments was performed to quantify PS-MEK1/2 levels. The data are expressed as mean ± S.E. The PS-MEK1/2 levels in untreated samples were arbitrarily set to 1. Fig. 10 . GH and insulin synergized in promoting cell proliferation. H4IIE cells were untreated (CTL), or treated with: G1, the first GH treatment for 1 h; G1/G2, the first GH treatment for 1 h, incubation in serumfree, GH-free medium for 3 h, followed by the second GH treatment; G1/I, the first GH treatment for 1 h, incubation in serum-free, GH-free medium for 2 h, followed by insulin treatment; G1/I/G2, the first GH treatment for 1 h, incubation in serum-free, GH-free medium for 2h, then insulin treatment for 1 h followed by the second GH treatment; CM, complete medium. Cell proliferation was examined by the BrdU incorporation assay. The data are expressed as mean ± S.E. Fig. 11 . Insulin increased the amount of MEK bound to KSR and restored a second GH-induced tyrosine phosphorylation of KSR. H4IIE cells were treated as described in the legend for Fig. 6 . Whole cell lysates were immunopreciptated with anti-KSR antibody and then subjected to Western blot analysis by antibodies for KSR, Raf-1, MEK1, and tyrosine phosphorylation (PY) (rows 1-4, respectively), or whole cell lysates were directly subjected to Western blot analysis with antibodies for KSR and STAT1 (rows 5 and 6, respectively). A) Representative Western blots of at least three separate experiments. HC: heavy chain of the anti-KSR antibody used for immunoprecipitation. B-D) Densitometric analysis of autoradiographs from 3 separate experiments was performed to quantify the ratio of KSR-associated Raf-1 to KSR, the ratio of KSR-associated MEK to Raf-1, and the ratio of PY-KSR to KSR. The data are expressed as mean ± S.E. The levels in untreated samples were arbitrarily set to 1. Fig. 12 . Proposed model for the interaction of Raf-1, MEK, and KSR following repeated GH treatments in the absence or presence of insulin. A) In untreated cells, Raf-1 and MEK binds to KSR. KSR is not tyrosine phosphorylated (PY) and Raf-1 and MEK are inactive. When cells are exposed to the first GH treatment, KSR is tyrosine phosphorylated and Raf-1 is activated. We hypothesize that, due to a conformational change caused by its tyrosine phosphorylation, KSR properly orients MEK with respect to Raf-1 and MEK is activated by Raf-1. B) Following the first GH treatment and incubation in serum-free, GH-free medium (SFM), the amount of Raf-1 bound to KSR increases, but the amount of MEK bound to KSR remains unchanged. The second GH treatment activates Raf-1, but only partially induces PY-KSR, as indicated by the smaller size of PY. The partial tyrosine phosphorylation of KSR fails to lead to a conformational change. Consequently, KSR does not bring Raf-1 and MEK together and MEK is not activated by Raf-1. C) In the presence of insulin, the amount of MEK bound to KSR increases and the second GH treatment restores the ability to induce PY-KSR. Tyrosine-phosphorylated KSR changes its conformation, brings Raf-1 and MEK together, and MEK is activated by Raf-1. Compared to the first GH treatment (A), the association of Raf-1/KSR and MEK/KSR increases following insulin pretreatment (C). This coincides with resensitization to GH; that is the ability of a second GH exposure following insulin pretreatment to induce MEK and ERK phosphorylation is returned to a level similar to that observed following the first GH treatment.
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